J
John A. McGrath
Researcher at King's College London
Publications - 674
Citations - 26684
John A. McGrath is an academic researcher from King's College London. The author has contributed to research in topics: Epidermolysis bullosa & Mutation. The author has an hindex of 75, co-authored 631 publications receiving 24078 citations. Previous affiliations of John A. McGrath include Ninewells Hospital & Southampton General Hospital.
Papers
More filters
Journal ArticleDOI
Genomic organization and amplification of the human desmosomal cadherin genes DSC1 and DSC3, encoding desmocollin types 1 and 3.
Neil V. Whittock,Debbie M. Hunt,Lisa Rickman,Sukhjit Malhi,Artemis P. Vogazianou,Lisa F. Dawson,Robin A.J. Eady,Roger S. Buxton,John A. McGrath +8 more
TL;DR: The desmosomal cadherins comprise the desmocollins and desmogleins and are involved in epithelial cell-cell adhesion and are potential candidates for genodermatoses involving epithelial tissues.
Journal ArticleDOI
Single‐cell transcriptomics in human skin research: available technologies, technical considerations and disease applications
TL;DR: The available technologies and technical considerations of single‐cell RNA sequencing are discussed and its applications to a broad spectrum of dermatological diseases are described.
Journal ArticleDOI
Cardiomyopathy diagnosed in the eldest child harbouring p.S24X mutation in JUP.
TL;DR: Patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR).
Journal ArticleDOI
Novel TGM5 mutations in acral peeling skin syndrome
Jaap J A J van der Velden,Michel van Geel,Ruud G. L. Nellen,Marcel F. Jonkman,John A. McGrath,Arti Nanda,Eli Sprecher,Maurice A.M. van Steensel,W.H. Irwin McLean,Andrew Cassidy +9 more
TL;DR: Both European and non‐European families carrying other mutations in the TGM5 gene are reported, with confirmed pathogenicity and functional analyses with a transglutaminase activity assay and alternative splicing by reverse‐transcribed PCR analysis.
Journal ArticleDOI
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome
Benjamin E. Ayres,David Gillatt,Sean McPhail,Angela M. Cottrell,John A. McGrath,Brian Cottier,Julia Verne,Rajendra Persad +7 more
TL;DR: It is agreed that delays to definitive treatment for high-risk bladder cancer should be minimized because it is a potentially lethal disease, and management options need to be discussed with colleagues in a multidisciplinary setting as well as with the patient.